TKI Famitinib Delays Progression in Advanced Colorectal Cancer

The tyrosine kinase inhibitor famitinib was associated with a significant improvement in progression-free survival among patients with advanced or metastatic colorectal cancer, according to the results of a phase II study conducted in China.

“Famitinib as a single agent treatment improved the progression-free survival by 1.3 months in patients with advanced/metastatic colorectal cancer,” said presenter Rui-Hua Xu, MD, PhD, of Sun Yat-sen University Cancer Center, Guangzhou, China, at the 2015 ASCO Gastrointestinal Cancers Symposium.

Famitinib is a small molecular, multi-target tyrosine kinase inhibitor that primarily targets VEGFR2, c-KIT, and PDGFR, and acts against angiogenesis. Xu and colleagues designed this study to evaluate the drug’s safety and efficacy in advanced colorectal cancer.